<DOC>
	<DOC>NCT00195481</DOC>
	<brief_summary>To determine the safety of sirolimus tablets in renal allograft recipients in a postmarketing surveillance setting.</brief_summary>
	<brief_title>Study Evaluating Sirolimus in Kidney Transplant Recipients in India</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients in End Stage Renal Disease who are above 13 years of age and weigh more than 40 kilograms. Patients scheduled to receive a kidney from a cadaveric donor, from a living unrelated donor or from a living related donor. Evidence of major infections at the time of sirolimus administration Use of any investigational drug or treatment up to 4 weeks prior to enrolling in the study and during the treatment phase. Females who are pregnant, breast feeding or in reproductive age group and not using a medically acceptable form of contraception</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Kidney</keyword>
	<keyword>Transplant</keyword>
</DOC>